专利诉讼可能会让2017年不再是无关紧要的事。

No matter how you slice it, 2016 was a banner year for biosimilars. Still, the high-stakes marketing, regulatory, and legal combat between originators and biosimilars is a long way from over. So far, the originators have been able to hold their ground and thwart the launch of biosimilars with patent lawsuits.

无论你如何看待，2016年都是生物类似药的丰收之年。尽管如此，原研药公司与生物类似药公司之间在高风险的营销、监管及法律方面的较量仍远未结束。到目前为止，原研药公司仍能够坚守阵地，并通过专利诉讼挫败生物类似药的推出。